<DOC>
	<DOCNO>NCT00296803</DOCNO>
	<brief_summary>The purpose study examine effect clopidogrel compare placebo marker inflammation subject metabolic syndrome receive background therapy include low dose aspirin .</brief_summary>
	<brief_title>PROCLAIM : Study Examining Effects Clopidogrel Compared Placebo Inflammation Subjects With Metabolic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<criteria>1 . Men woman least 18 year old 2 . Women must postmenopausal one year , surgically sterilize , use medically accept method contraception must agree use effective method contraception throughout study . 3 . Subject must meet 3 5 National Cholesterol Education Program/Adult Treatment Panel III ( NCEP/ATP III ) criterion classification metabolic syndrome : triglyceride &gt; /= 150 mg/dL ; blood pressure ( BP ) : systolic blood pressure ( SBP ) &gt; /= 130 mmHg/diastolic blood pressure ( DBP ) &gt; 85 mmHg ; fast glucose &gt; /= 110 mg/dL ; waist circumference : men &gt; 101.6 cm ( 40 ) /women &gt; 88.9 cm ( 35 ) ; highdensity lipoprotein ( HDL ) cholesterol : men &lt; 40 mg/dL/women &lt; 50 mg/dL . 4 . Subject highsensitivity Creactive protein ( hsCRP ) level &gt; /= 2.0 &lt; 10.0 mg/L Screening Visit ( Week 2 ) . 5 . Current medication regimen must stable six ( 6 ) week , i.e . initiation new prescription medication change dosage previously initiate medication within three month enter study . 6 . Subject normally active judge good health , base medical history , routine safety laboratory test ( Screening Visit , Week 2 ) , brief physical examination ( Week 2 ) . 1 . Intolerance contraindication use clopidogrel aspirin . 2 . Thrombocytopenia define platelet count &lt; 100,000/mm3 . 3 . Current use use within past 3 month oral anticoagulant , dipyridamole thienopyridine ( ticlopidine openlabel clopidogrel ) oral glucocorticoid . 4 . Daily aspirin excess 81 mg , chronic use nonsteroidal antiinflammatory agent . 5 . Use oral hormone replacement therapy oral contraceptive include transdermal patch . 6 . History pathologic bleeding ( i.e. , peptic ulcer intracranial hemorrhage ) . 7 . History chronic inflammatory disease recent medical event ( ) result tissue injury , infection , inflammation . 8 . Myocardial infarction , coronary artery bypass graft , angioplasty within 6 month prior Screening . 9 . Uncontrolled hypertension ( systolic blood pressure &gt; /= 180 mmHg diastolic blood pressure &gt; /= 100 mmHg ) Screening . 10 . History presence cancer past 2 year , except successfully resect basal cell carcinoma skin . 11 . Recent history ( within past 12 month ) alcohol substance abuse . 12 . Currently take another investigational study medication take investigational study medication within 30 day prior Screening Visit . 13 . Any condition Investigator believe would interfere evaluation subject , could put subject undue risk .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>metabolic syndrome</keyword>
</DOC>